GEN Exclusives

More »

GEN News Highlights

More »
Sep 10, 2012

Anti-Infectives Partnership Exploits DOS Compound Library

  • AstraZeneca and the Broad Institute inked a collaboration focused on identifying new antibacterial and antiviral drug targets. The partnership will leverage the Broad Institute’s library of 100,000 diversity-orientated synthesis (DOS) compounds, which has been designed to contain molecular shapes and structures not available elsewhere, as potential starting points for currently intractable biological targets.

    Under terms of the deal screening and hit-to-lead chemistry will take place in the Broad’s Chemical Biology Platform. AstraZeneca will optimize leads and carry out development and commercialization of resulting compounds. The firm says the collaboration has already yielded a number of potential new projects.

    “We believe new and collaborative approaches between the private and public sectors will help speed the discovery and development of new treatments, particularly for antibiotic-resistant infections,” comments Manos Perros, M.D., vp and head of AstraZeneca’s infection innovation medicines unit. “We are very pleased to work hand-in-hand with the Broad Institute to combine our unique resources and strong histories in innovation, discovery, and development to speed advancements in treatments for infections.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?